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ABSTRACT 
It has been suggested that not only the position but also the nature 
of the mutations of the ret protooncogene strongly correlate with the 
clinical manifestation of the multiple endocrine neoplasm type 2 
(MEN 2) syndrome. In particular, individuals with a Cys?-Arg sub- 
stitution should have a greater risk of developing parathyroid disease. 
We, therefore, analyzed 94 unrelated families from Germany with 
inherited medullary thyroid carcinoma (MTC) for mutation of the ret 
protooncogene. In all but 1 of 59 families with MEN 2A, germline 
mutations in the extracellular domain of the ret protein were found. 
Some 81% of the MEN 2A mutations affected codon 634. Phenotype- 
genotype correlations suggested that the prevalence of pheochromo- 
cytoma and hyperparathyroidism is significantly higher in families 
with codon 634 mutations, but there was no correlation with the 
nature of the mutation. In all but 1 of 27 familial MTC (FMTC) 
families, mutations were detected in 1 of 4 cysteines in the extracel- 
lular domain of the ret protooncogene. Half of the FMTC mutations 
affected codon 634. Mutations outside of codon 634 occurred more 
often in FMTC families than in MEN 2A families. In all but 1 of 8 MEN 
2B patients, de nouo mutations in codon 918 were found. These data 
confirm the preferential localization of MEN a-associated mutations 
and the correlation between disease phenotype and the position of the 
ret mutation, but there was no correlation between the occurrence of 
hyperparathyroidism or pheochromocytoma and the nature of the 
mutation. (J Clin Endocrinol Metab 81: 1780-1783, 1996) 
M EDULLARY THYROID carcinoma (MTC) may occur as part of the autosomal dominant, inherited, mul- 
tiple endocrine neoplasia type 2 (MEN 2) syndromes. Three 
hereditary forms of MEN 2 are known: MEN 2A is charac- 
terized by MTC in virtually 100% of patients, pheochromo- 
cytoma (pheo) in about 50% of patients, and/or primary 
hyperparathyroidism (pHpt) in about 20% of patients. The 
MEN 2B syndrome consists of MTC, pheo, mucosal neuro- 
mas, ganglioneuromatosis of the gut, and marfanoid habitus. 
The MTC only syndrome [also known as familial MTC 
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(F’MTC)] is not associated with other endocrinopathies, and 
inherited predisposition to MTC is the only disease feature 
(1). 
Germline mutations of the ret protooncogene have been 
identified as the underlying cause of the MEN 2 and FMTC 
syndromes (2-6). ret is a member of the family of receptor 
tyrosine kinases and is expressed in tissues derived from 
neural crest. Mutations at one of five codons for cysteine in 
the ret extracellular domain occur in MEN 2A and FMTC; 
MEN 2B is associated with a mutation of codon 918 in the 
intracellular tyrosine kinase domain of ret (7-10). These mu- 
tations convert ret into a dominant transforming gene (11). 
Identification of mutated gene carriers by DNA analysis al- 
lows earlier identification of subjects at risk in this familial 
cancer syndrome and provides the basis for preventative 
thyroidectomy (12, 13). 
Recently, two studies (3,5) showed an association between 
disease phenotype and the nature and position of the ret 
mutation. Although there is some overlap, mutations in cys- 
teine 634 are more strongly associated with MEN 2A than are 
mutations of cysteines farther from the cell membrane, which 
tend to occur in families with FMTC. Moreover, it has been 
suggested that patients with a Cys634-Arg substitution have 
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a greater risk of developing parathyroid disease (3), but this TABLE 2. Numbers of affected family members in each family 
could not be confirmed by others (5). with MEN BA/FMTC 
In the present study, we analyzed 94 unrelated German 
families with inherited MTC for ret mutations in exons 10, 11, 
and 16. We also examined the frequency, position, and nature 
of the mutations and the relation between genotype and 
phenotype. 
Affected/family 1 2 3 4 5 6 >7 
No. of families 10 9 11 6 5 4 14 
with MEN 2A 
No. of families 9 5 5 5 1 2 
with FMTC 
Subjects and Methods 
The members of the 94 families were classified clinically and bio- 
chemically and placed in 1 of 3 groups according to cancer syndrome, 
as defined in Table 1. The number of affected family members in each 
family with MEN 2A or FMTC is given in Table 2. The patient population 
for DNA analysis included 158 affected and 100 nonaffected individuals 
from 59 apparently independent kindreds with MEN 2A. There were 62 
affected and 32 nonaffected individuals who belonged to 27 kindreds 
with FMTC. We examined 8 MEN 2B patients; in 7 there was no family 
history of MEN 2B in other family members. Clinical classification of 
affected individuals was based on 1) an abnormal baseline or stimulated 
calcitonin level and/or pathological findings of C cell hyperplasia (clus- 
ters of C cells or 50 or more C cells/visual field at a magnification of 
x100) or MTC at the time of thyroidectomy; 2) biochemical, morpho- 
logical, or histological evidence of pheo; and/or 3) elevated serum 
calcium and PTH levels and/or parathyroid hyperplasia or adenoma at 
the time of parathyroidectomy. Screening for pheo and hyperparathy- 
roidism was performed annually in affected and at risk individuals, 
using excretion of catecholamines and serum calcium measurements. 
causing mutation creating a new restriction site had been identified in 
one family member, the amplified DNA fragments from other members 
of this family were usually analyzed solely by restriction enzyme anal- 
ysis. Restriction enzyme digests were carried out according to the in- 
structions of the supplier. Analysis of the DNA fragments was per- 
formed by PAGE with subsequent silver staining. 
Results 
We identified point mutations including two insertions in 
all but one MEN 2A families. In 48 of 59 families (81%), 
mutations were detected at codon 634 (exon 11; Table 3). In 
10 (17%) of the 59 MEN 2A families, a mutation at exon 10 
was found. At codon 634, the most frequent base change 
found in MEN 2A was TGC to CGC, which altered the amino 
acid sequence from cysteine to arginine. This mutation was 
found in 22 of 59 (37%) families (Table 4). 
Extraction of genomic DNA and amplification of exons 10, 
11, and 16 from the ret protooncogene 
Genomic DNA was isolated using the QIAMP blood kit (Qiagen, 
Hilden, Germany). PCR amplifications were carried out with the oli- 
gonucleotide primer Retl9S (5’-GCAG-CATTGTTGGGGGACA-3’) and 
RetlORb (5’-GTCCCGGCCACCCACT-3’) for exon 10 (size of amplified 
fragment 140 bp), Ret20S (5’~CATGAGGCAGAGCATACGCA-3’) and 
Ret2C (5’-GACAGCAGCACCGAGACGAT-3’) for exon ll(156 bp), and 
rRet16 (TAACCTCCACCCCAAGAGAG-3’) and fRetl6 (5’-AGGGAT- 
AGGG-CCTGGGCTTC3’) for exon 16 (192 bp). A total of 100 ng DNA 
were amplified in a Hybaid Omnigene apparatus (Hybaid, Teddington, 
UK) in a volume of 25 PL containing 1 pmol/L of each oligonucleotide 
primer, 10 mmol/L Tris-HCl (pH 8.3), 2.5 mmol/L MgCI,, and 1 U Tnq 
polymerase (Appligen, Heidelberg, Germany). The PCR was started 
with 1 min of denaturation at 95 C, followed by 35 cycles of 1 min each 
at 65,72, and 95 C, and, finally, 5 min at 72 C. The amplified DNA was 
analyzed on a 2% agarose gel and purified with the Qiagen Quickspin 
kit (Qiagen, Chatsworth, MA). 
By contrast, mutations in exon 11 were detected in 14 of 27 
(52%) FMTC families and in exon 10 in 12 of 27 (44%) F’MTC 
families (Table 3). Thus, the prevalence of mutations at codon 
634 is higher in MEN 2A families (81%) than in FMTC fam- 
ilies (52%; P < 0.008, by Fisher’s exact test, two-tail). 
In F’MTC, the position and type of mutation were more 
heterogeneous, suggesting a correlation between the posi- 
tion and the type of mutation and the spectrum of tissues 
involved. To test this, we correlated the presence of pheo or 
pHpt and mutations at codon 634 in all MEN 2A and FMTC 
families. The data in Table 5 show a strong association (P < 
0.004) between any mutation at codon 634 and the presence 
of pheo, but no association between the occurrence of pheo 
and any specific mutation at codon 634. The data in Table 6 
show an association between a mutation in codon 634 and the 
presence of parathyroid disease, but no association between 
pHpt and any specific mutation at codon 634. 
Exons 10 and 11 were screened for mutations by single strand con- 
formational polymorphism analysis. The amplified DNA fragments 
were denatured in formamide and 50 pmol/L ethylenediamine tetraac- 
etate and cooled on ice before loading onto the gel. Separation was 
carried out in a vertical gel electrophoresis apparatus in 1 X mutation 
detection enhancement (MDE@) gels (AT Biochem, Malvern, PA; exon 
10) or 12% polyacrylamide at 45 C and 300 millivolts (mV) for 6 h. The 
amplified and denatured DNA fragment representing exon 10 was sep- 
arated at 4 C and 6 V for 18 h. The fragment from exon 11 was separated 
at 45 C and 300 mV for 7 h. DNA bands were visualized by silver staining 
according to standard procedures. 
Discussion 
Mutations associated with MEN 2A or FMTC in German 
families 
PCR-amplified DNA was sequenced using either fluorescent-labeled 
dideoxy terminators (Prism Ready Reaction, Applied Biosystems kit, 
Foster City, CA) or one fluorescently labeled PCR primer. 
The mutation in codon 918 in exon 16 was detected by digest with the 
restriction enzyme Fokl, as described by Carlson et al. (7). If a MTC- 
Some 98% of German MEN 2A families have germline 
missense mutations in the extracellular domain of the ret 
protooncogene compared to 93-97% reported previously (2, 
3, 5, 6, 14-16). These mutations converted the cysteines at 
codons 609, 618, 620 (all in exon lo), or 634 (in exon 11) to 
other amino acids. In our MEN 2A series, codon 611 was not 
affected. The types of mutations were very similar to those 
described in previous studies (3, 5). The most frequent mu- 
tation in MEN 2A is located at codon 634, representing 83% 
TABLE 1. Classification of MEN 2 and FMTC 
MEN 2A: 
MEN 2B: 
FMTC: 
Families with MTC and at least 1 family member with either pheo or parathyroid disease or both 
Families with MTC, with or without pheo or parathyroid disease and the characteristic phenotype 
Families with MTC only and at least 2 family members with MTC or 1 family member with MTC 
and a mutation in the RET gene in which pheo and pHpt have been excluded by biochemical screening 
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TABLE 3. Distribution of ret mutations in 94 German families 
No. of mutations 
Codon Exon 10 11 Insertion 16 No Total 
609 611 618 620 634 918 
MEN2A 1 3 6 46 2 1 59 
FMTC 1 5 6 14 1 27 
MEN 2B 71 8 
TABLE 4. Distribution of amino acid sequence changes in MEN 
2A and FMTC 
MTC pheo pHpt 
MEN 2A 
Mutation MTC pheo MTC pHpt 
FMTC MTC 
(II = 18) 
(n = 36) 
(n = 5) (n = 27) 
634 
&t 10 10 2 5 
Tyr 2 9 1 5 
Trp 1 1 
GUY 1 1 
Phe 4 1 2 
Ser 2 2 1 
Insert 1 1 
620 
Arg 4 4 
TV 1 
Ser 1 1 1 
618 
Phe 2 
Ser 1 1 1 
kg 1 1 
GUY 1 
611 
Phe 1 
609 
GUY 1 
None 1 1 
TABLE 5. Mutations at codon 634 and pheo 
Disease phenotype 
MTC and pheo MTC no pheo 
P valuea 
No mutation at 634 
Any mutation at 634 
Specific mutation 
634 CGC (Arg) 
Other 
10 12 
0.004 
43 19 
20 7 
0.588 
23 12 
a Determined by Fisher’s exact test (two-tail). 
of all disease mutations in our series and 84-94% in recent 
studies (3,5). The substitution of arginine at codon 634 rep- 
resents the most frequent event of all changes at this codon: 
38% in our series and 4654% in recent work (3,5). 
Some 96% of German FMTC families have mutations com- 
pared to 67-86% reported previously (3,5, 17); 52% of mu- 
tations affect exon 11, and 44% affect exon 10. There is a 
strong correlation between the position of the mutation and 
disease phenotype; mutations in exon 11 (codon 634) are 
more strongly associated with MEN 2A than are mutations 
farther from the cell membrane (exon lo), which tend to 
occur in families with FMTC. Mutations elsewhere in ret may 
be responsible for the remaining few MEN 2A and FMTC 
families who do not have exon 10 or 11 mutations. For ex- 
ample, a mutation in ret exon 13 (codon 768), which codes for 
TABLE 6. Mutations at codon 634 and primary 
hyperparathyroidism 
Disease phenotype 
P value” 
MTC and pHpt MTC no pHpt 
No mutation at 634 2 24 
0.016 
Any mutation at 634 21 41 
Specific mutation 
634 CGC (Ax-g) 12 15 
0.117 
Other 9 26 
a Determined by Fisher’s exact test (two-tail). 
part of the intracellular kinase domain, was recently found 
in a FMTC family (18). 
Nonetheless, there is some overlap, as identical mutations 
(codon 634), but distinct phenotypic features, in families with 
MEN 2A and FMTC are observed. Beside misclassification of 
MEN 2A as FMTC families, i.e. if there are no cases of pheo 
or pHpt, this overlap may be explained by the influence of 
a modifier gene. Alternatively, MEN 2A and FMTC families 
may represent two, not clearly separable, subgroups of MEN 
2, in which the penetrance of pheo is high (MEN 2A) or low 
(FMTC) (19). The same is true for parathyroid disease, as, 
despite identical mutations, MTC can be associated in some 
families with either parathyroid disease or pheo and in oth- 
ers with both diseases. 
A codon 634 cysteine to arginine mutation does not predict 
parathyroid disease 
Any mutation at codon 634 was more likely to be associated 
with pheo or parathyroid disease. This is identical to other 
reports (3,5), in which there was a high prevalence of pheo (87% 
and 58%, respectively) in families with codon 634 mutations. 
German results do not support the earlier report of Mulligan et 
al. (9), who found a codon 634 cysteine to arginine mutation to 
be predictive of parathyroid disease. Only 32% of German fam- 
ilies with codon 634 cysteine to arginine mutations had para- 
thyroid disease [88% in Mulligan’s series (3) and 41% in 
Schuffenecker’s (5)]. Therefore, German results mirror those of 
Schuffenecker et al. (5). The discordance between our results 
and those of Mulligan might be explained by 1) the low number 
of families with pHpt in both studies; 2) the exclusion of one 
third of all families for statistical analysis because of a lack of 
documented screening for parathyroid disease in the Mulligan 
study, and/or 3) the result of a founder effect leading to a 
relatively high prevalence of a codon 634 CGC mutation in a 
particular population. 
In all but one of our seven patients with MEN 2B, there was 
a single identical point mutation at codon 918, a substitution 
of methionine by threonine in the catalytic core region of the 
tyrosine kinase domain. In only one familial case displaying 
the typical clinical features of MEN 2B was no mutation in 
codon 918 found; in this case no mutation in exons 10 and 11 
was identified. 
This suggests that a mutation at codon 918 is crucial for ret 
gene function. Recent results show that the MEN 2B mutation 
altered ret catalytic properties both quantitatively and qual- 
itatively, thus altering the substrate specificity of ret (11). 
Therefore, a mutation at codon 918 of the ret gene is the most 
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prevalent genetic defect causing MEN 2B, but rare MEN 2B 
cases are associated with different mutations that have yet to 
be defined. 
Conclusion 
Three clinically distinct, autosomal dominant, inherited 
conditions involving MTC have been associated with germ- 
line mutations in ret. These three syndromes, MEN 2A, MEN 
2B, and EMTC, involve different tissues in different combi- 
nations. We found a significant correlation between a par- 
ticular syndrome, and thus the spectrum of tissues involved, 
and the site of the mutation. The ret 918 mutation is exclu- 
sively seen in MEN 2B syndrome; the ret 634 mutation is 
preferentially associated with MEN 2A and is strongly pre- 
dictive of pheo and parathyroid disease. 
Addendum 
Meanwhile in the genetically unclassified MEN 2A family, 
a missense germline mutation in exon 13, and in the FMTC 
family in exon 14 could be detected, though the number of 
families with unidentified mutations decreased to one MEN 
2B family. 
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